Crossmark Global Holdings Inc. Sells 5,624 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Crossmark Global Holdings Inc. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 210,749 shares of the biopharmaceutical company’s stock after selling 5,624 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Gilead Sciences were worth $13,357,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Advisors Preferred LLC bought a new position in shares of Gilead Sciences in the second quarter worth about $26,000. Weaver Consulting Group bought a new position in shares of Gilead Sciences in the first quarter worth about $34,000. Legacy Advisors LLC bought a new position in shares of Gilead Sciences in the second quarter worth about $37,000. Evolution Wealth Advisors LLC bought a new position in shares of Gilead Sciences in the second quarter worth about $46,000. Finally, Motco lifted its holdings in shares of Gilead Sciences by 213.6% in the second quarter. Motco now owns 690 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 470 shares during the last quarter. 79.57% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have recently commented on GILD shares. Morgan Stanley set a $82.00 target price on shares of Gilead Sciences and gave the stock a “hold” rating in a report on Monday, July 15th. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Monday, July 15th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Monday, July 15th. BMO Capital Markets set a $82.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, July 31st. Finally, Royal Bank of Canada raised Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 price objective for the company in a research note on Monday, July 29th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $82.24.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.14. The business had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.54 billion. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The company’s revenue for the quarter was down 2.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.91 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 6.66 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.07%. The ex-dividend date of this dividend was Thursday, September 12th. Gilead Sciences’s dividend payout ratio is presently 40.98%.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 608 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $64.35, for a total transaction of $39,124.80. Following the completion of the sale, the executive vice president now owns 27,198 shares of the company’s stock, valued at approximately $1,750,191.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Olsen Per Wold sold 4,908 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $63.91, for a total transaction of $313,670.28. Following the sale, the director now directly owns 102,762 shares of the company’s stock, valued at approximately $6,567,519.42. The disclosure for this sale can be found here. Insiders have sold a total of 12,716 shares of company stock valued at $821,299 in the last three months. Insiders own 0.20% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Recommended Story: Percentage Decliners
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.